公开(公告)号：US20130345180A1

公开(公告)日：2013-12-26

申请号：US13837137

申请日：2013-03-15

Applicant: Novartis AG

Inventor： Rolf BAENTELI ,  Gerhard ZENKE ,  Nigel Graham COOKE ,  Rudolf DUTHALER ,  Gebhard THOMA ,  Anette VON MATT ,  Toshiyuki HONDA ,  Naoko MATSUURA ,  Kazuhiko NONOMURA ,  Osamu OHMORI ,  Ichiro UMEMURA ,  Klaus HINTERDING ,  Christos PAPAGEORGIOU

IPC: C07D239/48 ,  A61K31/506 ,  C07D403/12 ,  C07D401/12 ,  A61K31/55 ,  A61K31/5377 ,  C07D417/12 ,  A61K45/06 ,  A61K31/505

CPC classification number: C07D239/48 ,  A61K31/505 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D417/12

Abstract: There are provided compounds of formula I wherein X, R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as indicated in claim 1, useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

Abstract translation: 提供式I化合物，其中X，R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8和R 9如权利要求1所述，其可用于ZAP-70和/或Syk抑制起作用或 由与FAK连接的信号级联故障引起的。

公开(公告)号：US20240043425A1

公开(公告)日：2024-02-08

申请号：US18319585

申请日：2023-05-18

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;






wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220177432A1

公开(公告)日：2022-06-09

申请号：US17677538

申请日：2022-02-22

Applicant: NOVARTIS AG

Inventor： Gebhard THOMA

IPC: C07D213/74 ,  C07D401/12 ,  A61K31/444

Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.

公开(公告)号：US20250092042A1

公开(公告)日：2025-03-20

申请号：US18924066

申请日：2024-10-23

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a method for manufacturing a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein.

公开(公告)号：US20180354904A1

公开(公告)日：2018-12-13

申请号：US15778783

申请日：2016-11-24

Applicant: NOVARTIS AG

Inventor： Gebhard THOMA

IPC: C07D213/74 ,  A61K31/444

Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.